Drugs / LY3556050
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06052462 | Sep → Nov 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05615467 | Nov → Dec 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04156750 | Nov 2019 → Aug 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05341102 | Sep 2016 → Jun 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06074562 | Oct 2023 → Jun 2025 | diabetic polyneuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT04874636 | May 2021 → Feb 2022 | chronic pain syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT04707157 | May 2021 → Jun 2022 | diabetic polyneuropathy | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT04627038 | Nov 2020 → Oct 2021 | osteoarthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT05986292 | Jan 2020 → Apr 2027 expected | chronic pain syndrome, diabetic polyneuropathy, osteoarthritis, knee | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3556050 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05986292 ↗ |
| Route | Oral | “LY3556050 administered orally.” NCT04156750 ↗ |